We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App





Commonly Used Antiviral and Anti-Malarial Drugs Found to Work Similarly to Gilead’s Remdesivir in Preventing SARS-CoV-2 Replication

By HospiMedica International staff writers
Posted on 26 Mar 2021
Researchers have found that three commonly used antiviral and antimalarial drugs which work similarly to Gilead Sciences’ (Foster City, CA, USA) antiviral drug remdesivir are effective in vitro at preventing replication of SARS-CoV-2, the virus that causes COVID-19.

The work by an international team of researchers, including from NC State University (Raleigh, NC, USA), also underscores the necessity of testing compounds against multiple cell lines to rule out false negative results. The researchers looked at three antiviral drugs that have proven effective against Ebola and the Marburg virus: tilorone, quinacrine and pyronaridine.

The compounds were tested in vitro against SARS-CoV-2, as well as against a common cold virus (HCoV 229E) and murine hepatitis virus (MHV). Researchers utilized a variety of cell lines that represented potential targets for SARS-CoV-2 infection in the human body. They infected the cell lines with the different viruses and then looked at how well the compounds prevented viral replication in the cells.

The results were mixed, with the compounds’ effectiveness depending upon whether they were used in human-derived cell lines versus monkey-derived cell lines, known as Vero cell lines. The next steps for the research include testing the compounds’ effectiveness in a mouse model and further work on understanding how they inhibit viral replication.

“In the human-derived cell lines, we found that all three compounds worked similarly to remdesivir, which is currently being used to treat COVID-19,” said Frank Scholle, associate professor of biology at NC State and co-author of the research. “However, they were not at all effective in the Vero cells.”

“One of the more interesting findings here is that these compounds don’t just prevent the virus from potentially binding to the cells, but that they may also inhibit viral activity because these compounds are acting on the lysosomes,” said Ana Puhl, senior scientist at Collaborations Pharmaceuticals and co-corresponding author of the research. “Lysosomes, which are important for normal cell function, are hijacked by the virus for entry and exit out of the cell. So, if that mechanism is disrupted, it cannot infect other cells.”

“It’s also interesting that these compounds are effective not just against SARS-CoV-2, but against related coronaviruses,” added Scholle. “It could give us a head start on therapies as new coronaviruses emerge.”

Related Links:
NC State University
Gilead Sciences

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Needle Guide Disposable Kit
Verza
New
Captivator EMR Device
Captivator Endoscopic Mucosal Resection Device
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: Samples of heart tissue from the study (Photo courtesy of Nathan Gianneschi/Northwestern University)

New Potent Injectable Therapy Could Prevent Heart Failure After Heart Attack

According to the U.S. Centers for Disease Control and Prevention, 6.7 million Americans aged 20 and older are living with heart failure, a condition in which the heart cannot pump enough blood to meet... Read more

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.